Skip to content
Study details
Enrolling now

Early Screening and Treatment of Heart Complication in Sickle Cell Disease

Inova Health Care Services
NCT IDNCT07023666ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

100

Study length

about 1.7 years

Ages

18+

Locations

2 sites in VA

About this study

Researchers are testing whether early screening for heart complications and treatment for iron overload can prevent heart problems and reduce hospitalizations in people with sickle cell disease. The trial will involve using medications like deferasirox, deferiprone, or deferoxamine, along with tests such as echocardiography and electrocardiograms (ECG).

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Deferasirox
  • 2.Take Deferiprone
  • 3.Take Deferoxamine
  • +2 more
PhasePhase 2
DrugDeferasirox
Routeoral
Primary goalIncidence of Hospitalization for Sickle Cell Disease Related Complications

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low10%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

deferasirox, deferiprone, deferoxamine

Drug routes

oral (Oral Tablet)

Endpoints

Primary: Incidence of Hospitalization for Sickle Cell Disease Related Complications, Length of Stay for SCD-Related Complications

Devices

diagnostic